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Summary
Eculizumab is the first and only medication approved for paroxysmal noc-
turnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome
(aHUS) treatment. However, eculizumab safety based on long-term phar-
macovigilance is unknown. This analysis summarises safety data collected
from spontaneous and solicited sources from 16 March 2007 through 1
October 2016. Cumulative exposure to eculizumab was 28 518 patient-
years (PY) (PNH, 21 016 PY; aHUS, 7502 PY). Seventy-six cases of
meningococcal infection were reported (025/100 PY), including eight fatal
PNH cases (003/100 PY). Susceptibility to meningococcal infections
remained the key risk in patients receiving eculizumab. The meningococcal
infection rate decreased over time; related mortality remained steady. The
most commonly reported serious nonmeningococcal infections were pneu-
monia (118%); bacteraemia, sepsis and septic shock (111%); urinary tract
infection (41%); staphylococcal infection (26%); and viral infection
(25%). There were 434 reported cases of eculizumab exposure in pregnant
women; of 260 cases with known outcomes, 70% resulted in live births.
Reporting rates for solid tumours (06/100 PY) and haematological
malignancies (074/100 PY) remained stable over time. No new safety sig-
nals affecting the eculizumab benefit-risk profile were identified. Continued
awareness and implementation of risk mitigation protocols are essential to
minimise risk of meningococcal and other Neisseria infections in patients
receiving eculizumab.
Keywords: paroxysmal nocturnal haemoglobinuria, atypical haemolytic
uraemic syndrome, eculizumab, pharmacovigilance, safety.
Paroxysmal nocturnal haemoglobinuria (PNH) and atypical
haemolytic uraemic syndrome (aHUS) are rare, chronic, dis-
eases that may be life-threatening without treatment (Brod-
sky, 2014; Jang et al, 2016; Loschi et al, 2016; Fakhouri et al,
2017). Both diseases are caused by uncontrolled complement
activation, resulting in intravascular haemolysis in PNH and
systemic thrombotic microangiopathy (TMA) in aHUS
(Noris & Remuzzi, 2009; Brodsky, 2014). Patients are at risk
for significant complications, such as thrombosis, haemolytic
anaemia, pulmonary hypertension and fatigue in PNH, and
haemolytic anaemia and systemic organ impairment or fail-
ure in aHUS (Peffault de Latour et al, 2008; Noris &
Remuzzi, 2009; Noris et al, 2010; Sallee et al, 2010; Muus
et al, 2011; Fremeaux-Bacchi et al, 2013; Azukaitis et al,
2014; Brodsky, 2014).
Eculizumab (Soliris; Alexion Pharmaceuticals, Inc., Bos-
ton, MA, USA), is the first approved medication for patients
with PNH (in 2007) or aHUS (in 2011) (https://www.medic
ines.org.uk/emc/product/362/smpc/print; http://alexion.com/
Documents/Soliris_USPI.aspx), and has been recently
approved for refractory generalised myasthenia gravis in Eur-
ope (European Medicines Agency, 2017a) and Japan (http://
www.soliris.jp/common/pdf/tempu_bunsho.pdf), and gener-
alised myasthenia gravis in the United States. The safety and
efficacy of eculizumab therapy in PNH and aHUS were
established in several prospective clinical trials, but long-term
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post-marketing safety monitoring in broader populations is
essential for orphan drugs. In patients with PNH, treatment
with eculizumab was associated with significant reductions in
intravascular haemolysis, thromboembolism, transfusion
requirements, anaemia, and fatigue, and improved quality of
life (Hillmen et al, 2006, 2007, 2013; Brodsky et al, 2008). In
patients with aHUS, eculizumab inhibited TMA, improved
renal function and haematological outcomes, and improved
quality of life (Legendre et al, 2013; Licht et al, 2015;
Fakhouri et al, 2016; Greenbaum et al, 2016). Eculizumab
therapy has also been associated with improved survival in
both clinical settings (Kelly et al, 2011; Johnson et al, 2014).
As a first-in-class C5 inhibitor, the long-term safety of ecu-
lizumab was unknown at the time of approval and, given the
known increased risk of infection associated with complement
deficiency (Figueroa & Densen, 1991), enhanced post-market-
ing pharmacovigilance surveillance was established, including
patient support programmes and post-approval observational
studies. The purpose was to collect data in a larger and
broader patient population in order to ascertain the safety
profile of eculizumab, particularly as it relates to rare but
potentially clinically significant adverse events (AEs) that
would not otherwise be observed in clinical studies. AEs of
special interest and other safety outcomes were closely moni-
tored as part of the post-marketing assessment of eculizumab
safety, including meningococcal infections, other serious
infections, use in pregnancy and potential for developing
malignancies. Since Neisseria meningitidis is primarily cleared
by terminal complement components, it has been established
that eculizumab-treated patients are at increased risk for
developing meningococcal infections (Figueroa & Densen,
1991; Rother et al, 2007). To minimise this risk, mitigation
measures, including meningococcal vaccination, safety cards
and educational materials for patients and physicians are
implemented worldwide. Use of eculizumab in pregnant
patients has been followed in post-marketing surveillance
because pregnancy was an exclusion criterion in the eculizu-
mab registration trials. Historically, pregnancy has been dis-
couraged in patients with PNH, and the management of PNH
during pregnancy has been challenging because pregnant
patients can have more severe intravascular haemolysis, and
morbidity and mortality are higher among pregnant women
with PNH versus those with PNH who are not pregnant; these
risks continue to be high during the post-partum period
(Kelly et al, 2015). In terms of aHUS, data on pregnancy out-
comes is very scarce but due to complement activation,
patients have severe manifestations and poor outcomes
(Huerta et al, 2018; Kozlovskaya et al, 2018). Assessment of
potential risk of malignancy was also a priority even though
anti-tumour immunity is not expected to be affected in
patients with late complement deficiency.
The objective of this analysis is to summarise 10 years of
post-marketing safety data collected from spontaneous and
solicited reports of patients with PNH and aHUS who were
treated with eculizumab. The results from this analysis are
also considered in the context of AEs reported in the eculizu-
mab clinical trials.
Methods
Data sources
Safety data regarding eculizumab use in the treatment of
PNH and aHUS were collected and recorded in the Alexion
pharmacovigilance database. Data were analysed for the per-
iod from 16 March 2007 (US Food and Drug Administration
and Center for Drug Evaluation and Research, 2007) (the
date of first marketing authorization) through 1 October
2016 (for PNH and aHUS patients only). From a pharma-
covigilance perspective, an AE can be any unfavourable or
unintended sign, symptom or disease temporally related with
the use of a medicinal product, whether or not related to the
medicinal product (European Medicines Agency, 2017b). AE
reports were obtained in a solicited and unsolicited manner.
Solicited reports were obtained from organised data collec-
tion methods (including, but not limited to, patient support
programmes, disease management programmes, surveys of
patients by health care providers, observational studies, sales
representatives and medical science liaisons). Solicited reports
included AEs identified through patient support programmes
and from PNH and aHUS registries; solicited sources
reported AEs regardless of whether there was causal associa-
tion with eculizumab. Spontaneous (unsolicited) AEs were
voluntarily reported by health care professionals, consumers,
and competent authorities worldwide (e.g., US Food and
Drug Administration, European Medicines Agency) or
retrieved from published scientific literature using a defined
search strategy and terms compiled and analysed by the
Institute for Scientific and Technical Information, Vandoeu-
vre-les-Nancy, France (Table SI). Data from Alexion-spon-
sored clinical trials of eculizumab were excluded from this
analysis.
Data collection
Safety data were structured by individual case safety reports
(ICSRs) that included one or more AEs, not by individual
patients. Due to confidentiality rules or limited information
reported on patients, a given AE may have been reported
multiple times from different sources with limited possibility
for reconciliation and duplicate removal. Adverse event
reports were coded according to preferred terms defined by
the Medical Dictionary for Regulatory Activities (MedDRA
V18.1).
Database inquiries
All post-marketing ICSRs were searched using MedDRA pre-
ferred terms. ICSRs from solicited sources, where events were
clearly considered unrelated to eculizumab treatment by both
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the reporter and Alexion, were excluded from the analysis.
When no causality assessments were reported by a solicited
source, events were considered possibly related by default
and retained in the analysis.
Data analysis
Data were analysed using summary tables of cumulative AEs
and serious AEs generated from the Alexion pharmacovigi-
lance database in order to identify any emerging events, unu-
sual trends or reporting frequencies. Duplicate reports were
reconciled whenever possible. Cumulative post-marketing
exposure to eculizumab was calculated by adding the expo-
sure in person-months of new patients, discontinuing
patients and continuing patients for each indication during
the analysis period. Rates of AEs were calculated as number
of events per 100 patient-years (PY). Other quantitative data
were reported using descriptive statistics.
Data sharing
Qualified academic investigators may request aggregate data
contained in relevant sections of the PSUR 14.1 (http://alex
ion.com/research-development). Further details regarding
data availability (including participant-level clinical data),
instructions for requesting information and our data disclo-
sure policy will be available on the Alexion.com website
(http://alexion.com/research-development).
Results
Eculizumab exposure and AE reports
The global cumulative post-marketing exposure to eculizu-
mab from 16 March 2007 to 1 October 2016, was 28 5177
PY, including 21 0157 PY in patients with PNH (20 5113
PY in adults; 5044 PY in children <18 years of age) and
75019 PY in patients with aHUS (54914 PY in adults;
20105 PY in children). Of the 2833 reported cumulative
AEs per 100 PY collected in the Alexion pharmacovigilance
database, 711 per 100 PY (251%) were from spontaneous
reports and 2122 per 100 PY (749%) were from solicited
reports. Overall, 36% were serious AEs; 43% of spontaneous
AE reports and 336% of solicited AE reports were serious.
Solicited reports originated mostly from patient support pro-
grammes (more than 80%) whose reporters were trained to
report all AEs regardless of causality; such AEs would, there-
fore, include those that reflect disease manifestation as well
as those that may be caused by eculizumab.
Most frequently reported AEs
The most frequently reported AEs, which largely reflect dis-
ease manifestation, are summarised in Tables I, II and SII.
AEs occurring at rates greater than nine events per 100 PY
included decreased haemoglobin, fatigue, pyrexia and head-
ache. Deaths occurring during treatment with eculizumab
were reported. With the exception of deaths due to meningo-
coccal infections (see below), there were no reports of fatal
outcomes with a causal association to eculizumab treatment.
Eculizumab was well tolerated and the majority of reported
events associated with eculizumab were not serious. No new
safety concerns emerged regarding eculizumab-related infu-
sion reactions (https://www.medicines.org.uk/emc/product/
362/smpc/print; http://alexion.com/Documents/Soliris_USPI.a
spx).
Adverse events of special interest
Meningococcal infections. Seventy-six cases of meningococcal
infection were reported, representing an overall rate of 025
reports per 100 PY (024 per 100 PY for PNH and 029 per
100 PY for aHUS). There were eight fatal meningococcal
infection cases (003 per 100 PY), all of which occurred in
patients with PNH. The rate of meningococcal infections
tended to decrease over time, ranging from 057 per 100 PY
in 2007 to 016 per 100 PY in 2016, with no obvious geo-
graphical predilection noted (data not shown) and serogroup
B remained the most frequently reported meningococcal
infection despite introduction of MenB vaccine in 2013. The
mortality rate associated with meningococcal infections
remained stable over time (Fig 1), with no death observed
between 2012 and 2016 (Table III). No obvious geographical
predilection was noted after the introduction of MenB vacci-
nation (data not shown). Demographics and characteristics
of patients with meningococcal infection are summarised in
Table IV. The majority of reported meningococcal infections
occurred in patients aged 16–44 years old. Almost all cases
occurred in patients with previous confirmed meningococcal
vaccination (vaccination status was not reported in 5% of
patients). Importantly, patients were not vaccinated against
all serotypes of N. meningitidis because the availability of
specific vaccines varied across regions.
Frequencies and outcomes of meningococcal-related AEs
are summarised in Table V. Sepsis was the most frequently
reported presentation of meningococcal infection. In 39 cases
(508%), patients fully recovered or were improving at the
time of report. This includes four patients who recovered
with sequelae. Outcomes were unknown or not yet reported
in 29 cases (381%).
The eight patients (105%) with fatal outcomes were 22–
40 years of age (Table III). All eight had received meningo-
coccal vaccination, although not against all serotypes.
Other serious infections. Reported rates of serious, non-
meningococcal infections are provided in Table VI. No age-
related trends were observed within the subgroups with PNH
or aHUS. Although there was a higher rate of serious non-
meningococcal infection observed in adults aged 18–65 years,
exposure was also higher in this age group compared with
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paediatric patients. Importantly, this pattern of infection rate
corresponds to the age range of patients treated with eculizu-
mab (Tables SIIIA,B).
Among patients experiencing serious infections, the most
commonly reported serious nonmeningococcal infections
were pneumonia (118%); bacteraemia, sepsis and septic
shock (111%); urinary tract infection (41%); staphylococcal
infection (26%); and viral infection (not otherwise specified;
25%). All patients with serious, nonmeningococcal infec-
tions had severe underlying conditions, comorbidities or
treatments that could have compromised their immune
systems.
Neisseria infections other than N. meningitidis infections
also have been reported, including disseminated
gonococcal infections (17%) and sepsis with other Neisse-
ria species such as Neisseria cinerea, subflava/sicca, or elon-
gata (11%).
The overall reporting rate for Aspergillus infection was
013 cases per 100 PY (039 per 100 PY in aHUS; 004 per
100 PY in PNH). All patients had severe and multiple con-
founding factors, such as recent transplant and immunosup-
pressive treatment. Sixty-three percent of the reported cases
were fatal.
Outcomes in pregnancy. Eculizumab exposure was reported
in a total of 434 women during their pregnancy; 335 patients
(77%) with PNH and 99 patients (23%) with aHUS
(Table VII). Seventy percent of pregnancies (72% in PNH
and 59% in aHUS) with reported outcomes resulted in live
births; abortion was induced in 78% of pregnancies in PNH
and in 204% in aHUS. One case of serious infection was
reported in a neonate born to a mother treated with eculizu-
mab. However, this infection occurred 12 days post-delivery
and was considered by the treating physician as unlikely to
Table I. Most frequently reported AEs (by MedDRA preferred term) in patients with PNH.
MedDRA preferred term
Spontaneous number of AEs per
100 PY
Solicited number of AEs per 100
PY
Total
Serious Nonserious Serious Nonserious
Haemoglobin decreased 24 09 127 34 194
Fatigue 04 17 16 39 176
Pyrexia 16 09 39 33 97
Headache 06 10 14 62 92
Haemolysis 27 05 35 23 90
Dyspnoea 05 06 18 43 72
Abdominal pain 07 06 21 37 71
Platelet count decreased 06 05 37 22 71
Transfusion 06 0 50 02 58
Incidence rates are expressed as per 100 PY.
AEs, adverse events; MedDRA, Medical Dictionary for Regulatory Activities; PNH, paroxysmal nocturnal haemoglobinuria; PY, patient-years.
Table II. Most frequently reported AEs (by MedDRA preferred term) in patients with aHUS.
MedDRA preferred term
Spontaneous number of AEs per
100 PY
Solicited number of AEs per 100
PY
Total
Serious Nonserious Serious Nonserious
Haemoglobin decreased 14 07 69 22 111
Fatigue 02 11 10 82 105
Death 21 0 65 0 86
Pyrexia 15 09 36 26 85
Unevaluable event 04 0 67 04 76
Headache 05 08 11 46 71
Platelet count decreased 07 06 31 19 64
Vomiting 06 04 19 26 55
Dyspnoea 06 06 21 21 54
Nausea 04 05 13 30 52
Incidence rates are expressed as per 100 PY.
AEs, adverse events; aHUS, atypical haemolytic uraemic syndrome; MedDRA, Medical Dictionary for Regulatory Activities; PY, patient-years.
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be related to eculizumab. Eculizumab was given as rescue
therapy in a patient who was 4 months pregnant experienc-
ing onset of severe aHUS-related neurological complications
and had already received plasma exchanges. She experienced
a hospital-acquired vancomycin-resistant enterococcus infec-
tion. This event was considered unlikely to be related to ecu-
lizumab by the treating physician, given the severe
underlying conditions with plasma exchanges and catheteri-
zation, as well as the high virulence and pathogenicity of
nosocomial vancomycin-resistant enterococcal infections, the
most commonly acquired type of hospital infection.
Outcomes in breastfeeding mothers. There were 31 patients
reported to have breastfed while receiving eculizumab; 20
patients with PNH and 11 patients with aHUS. One patient
experienced a painful breast lump, mastitis, sepsis and fever.
The remaining 30 patients (and neonates) did not experience
any AEs associated with breastfeeding.
Malignancies. Malignancies were reported in patients with
PNH (26 reports per 100 PY) and aHUS (31 reports per
100 PY) (Table VIII). The mean time to onset of malig-
nancy after the initial dose of eculizumab was 22 years in
the 16% of patients with PNH for whom data were avail-
able, versus 10 years in the 125% of patients with aHUS
with available data. As expected, the reported haematologi-
cal pathologies in patients with PNH were higher than in
patients with aHUS. The reporting rate of approximately
074 per 100 PY remained stable over time. With respect to
solid tumours, skin neoplasms were more frequently
reported in patients with PNH (15% of solid tumours)
than in those with aHUS (5% of solid tumours). Otherwise,
no trends were observed regarding specific types of solid
tumours. The reporting rate for solid tumours remained
stable over time at approximately 06 per 100 PY. Reported
rates of malignancies stratified by age and sex are
summarised in Tables SIVA,B.
Hepatic dysfunction. Several patients with underlying hepatic
dysfunction who were treated with eculizumab, including
patients with PNH who had Budd-Chiari syndrome, cirrhosis
or other severe hepatic conditions, were represented in the
database. Overall, no clinically relevant differences were
observed in the frequency or type of AEs associated with ecu-
lizumab treatment in patients with or without a history of
liver dysfunction.
Discussion
This report is the largest compilation of pharmacovigilance
data on eculizumab exposure to date, including 10 years of
post-marketing surveillance. This analysis reflects 28 518 PY
of global cumulative exposure to eculizumab (21 016 PY in
PNH and 7502 PY in aHUS) compared with 711 PY of
cumulative exposure across clinical trials (Hillmen et al,
2006, 2013; Brodsky et al, 2008; Kanakura et al, 2011; Legen-
dre et al, 2013; Licht et al, 2015; Fakhouri et al, 2016;
Greenbaum et al, 2016).
This study has enabled the analysis of long-term trends in
reported AEs, including AEs of special interest, in patients
receiving eculizumab. Meningococcal infections are of partic-
ular interest because there is a well-established and pre-
dictable risk of infection from Neisseria species that is directly
related to the mechanism of action of eculizumab (Rother
et al, 2007; McNamara et al, 2017). Overall, the cumulative
reporting rate of meningococcal infection in eculizumab-
treated patients tended to decline over time following the ini-
tial approval of eculizumab, then remained relatively stable
over the most recent 5 years, at approximately 025 per 100
PY. The distribution of meningococcal infections by age (16-
to 25-year-olds have a higher infection rate) is also similar to
that reported in the general population (Atkinson et al, 2016;
Centers for Disease Control and Prevention, 2017). These
findings are also consistent with those reported in clinical
studies (083 events per 100 PY) (Drug Safety and Risk
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Meningococcal 
infection 0∙57 0∙63 0∙3 0∙51 0∙42 0∙28 0∙21 0∙27 0∙21 0∙16
Mortality 0 0∙12 0∙05 0∙09 0∙08 0∙08 0∙05 0∙04 0∙03 0∙03
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Fig 1. Rates of meningococcal infection and
associated mortality per 100 PY from 2007 to
2016. Data are inclusive of both PNH and
aHUS (indications approved in March 2007
and September 2011, respectively). Data
expressed as cumulative rate per 100 PY.
aHUS, atypical haemolytic uraemic syndrome;
PNH, paroxysmal nocturnal haemoglobinuria;
PY, patient-years.
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Management Advisory Committee, 2014). Compared with the
general population, the incidence rates for meningococcal
infections are 8000- to 10 000-fold higher in patients with late
complement component deficiency (Figueroa & Densen,
1991; Tedesco, 2008), and 1000- to 2000-fold higher in
patients receiving eculizumab under the risk mitigation mea-
sures (McNamara et al, 2017). It should be noted that those
with inherited complement deficiency are at risk from birth,
whereas those treated with eculizumab are not at risk before
they start complement-inhibitor therapy. These findings sug-
gest that the current mitigation measures are generally effec-
tive. While 95% of patients with meningococcal infections
were reported to have received vaccinations, patients were not
vaccinated against all serotypes. Of note, the vaccine against
serogroup B disease was not approved in the European Union
until 2013 (European Medicines Agency, 2013), and is not
available worldwide. Furthermore, ex vivo data have shown
that vaccination may not fully suppress the risk of
meningococcal infection due to inhibition of the
opsonophagocytic activity and complement-dependent cyto-
toxicity required for eradication of Neisseria (Sprong et al,
2003; Konar & Granoff, 2017).
In this analysis, eight deaths occurred in PNH patients
with meningococcal infections, largely due to a delay in diag-
nosis and/or treatment of infection. No deaths due to
meningococcal infections were observed in aHUS patients.
Importantly, the fatality rate in this analysis (105%) was
similar to that reported in the general population (86%)
(Centers for Disease Control and Prevention, 2016). These
findings underscore the need for heightened awareness
among patients and physicians regarding the risk of
meningococcal infection. Information about risk mitigation
measures can also be found in patient education and provi-
der certification materials from the Risk Evaluation and Miti-
gation Strategy programme for eculizumab (www.solirisre
ms.com). Recommendations from the US Advisory
Table IV. Demographics, vaccination status, and identified serotype among patients with meningococcal infection.*
Patient characteristic PNH (n = 52) aHUS (n = 24) Total (n = 76)
Age group, years, n (%)
0–5 0 2 (83) 2 (26)
6–15 2 (38) 4 (167) 6 (79)
16–25 23 (442) 11 (458) 34 (447)
26–44 18 (346) 5 (208) 23 (303)
45–65 5 (96) 0 5 (66)
>65 1 (19) 0 1 (13)
Not reported 3 (58) 2 (83) 5 (66)
Sex
Female 29 (558) 14 (583) 43 (566)
Male 23 (442) 9 (375) 32 (421)
Not reported 0 1 (42) 1 (13)
Time to onset of meningococcal infection after first dose of
eculizumab (days), median (range)
272 (4–2247)* 502 (43–1481)† –
Vaccination status, n (%)
All confirmed vaccinations* 51 (981) 21 (875) 72 (947)
Not reported 1 (19) 3 (125) 4 (52)
Identified serogroup, n (%) 30 (577) 15 (625) 45 (592)
B 13 (433) 6 (400) 19 (422)
Y 6 (200) 3 (200) 9 (200)
C 7 (233) 1 (67) 8 (178)
W 0 4 (267) 4 (89)
E 0 1 (67) 1 (22)
X 1 (33) 0 1 (22)
Z 1 (33) 0 1 (22)
Noncapsulated apathogenic 1 (33) 0 1 (22)
Negative in serotypes A, B, C, W135, Y 1 (33) 0 1 (22)
Unknown serotype, n (%) 22 (423) 9 (375) 31 (408)
Data expressed as number (percentage) by age group, sex, and vaccination status.
“Unknown” refers to unreported data.
aHUS, atypical haemolytic uraemic syndrome; PNH, paroxysmal nocturnal haemoglobinuria.
*Type of vaccine may be unknown; only 34 cases had sufficient information to calculate the median value.
†Only 11 cases had sufficient information to calculate the median value. Patients were not vaccinated against all Neisseria meningitidis serogroups;
and vaccination is not 100% effective.
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Committee on Immunization Practices encourage vaccination
against A, C, W, Y and B serotypes for patients receiving
eculizumab (McNamara et al, 2017; O’Leary & Kimberlin,
2017). However, as meningococcal vaccination may not pre-
vent all cases of meningococcal infection in eculizumab-treat-
ed patients (Konar et al, 2016; Konar & Granoff, 2017;
McNamara et al, 2017; O’Leary & Kimberlin, 2017), the Cen-
ters for Disease Control and Prevention suggests that consid-
eration be given to appropriate use of antibiotic prophylaxis;
all patients should be monitored for early signs of meningo-
coccal infection.
The susceptibility to develop serious infections with
Neisseria species other than meningococcus was confirmed.
Infections with organisms considered to be non-pathogenic
in immunocompetent patients, such as Neisseria sicca/sub-
flava, were observed. Most of the reported gonococcal infec-
tions (89%) presented as disseminated gonococcal infections,
which are rare in the general population (<1%). This severity
might be related to eculizumab treatment that prevents effi-
cient serum bactericidal activity; however, other reasons, such
as the underlying pathophysiology of the disease and
concomitant medications may also be contributing factors.
Rates of serious nonmeningococcal infections reported
herein are consistent with those reported in the clinical trials
of eculizumab in PNH (Hillmen et al, 2006, 2013; Brodsky
et al, 2008) and aHUS (Legendre et al, 2013; Licht et al,
2015; Fakhouri et al, 2016; Greenbaum et al, 2016). In the
only double-blind, randomised, placebo-controlled trial of
eculizumab in 87 patients with PNH (Hillmen et al, 2006),
serious nonmeningococcal infections were reported in similar
proportions of eculizumab-treated and untreated patients
with PNH (2% vs. 6%, respectively). Outside of the clinical
trial programme, severe infections have been reported in up
to 18% (Nishimura et al, 2004) and were identified as the
cause of death in 25–40% of mortalities reported in
untreated patients with PNH (Jang et al, 2016; Yu et al,
2016). Infections have been identified as precipitating events
in patients with aHUS (Noris et al, 2010; Schifferli et al,
2010; Geerdink et al, 2012; Fremeaux-Bacchi et al, 2013;
Campistol et al, 2015); it is important to note that immuno-
suppression may play a role in these infections because many
aHUS patients receive dialysis or renal transplantation (Noris
et al, 2010; Schifferli et al, 2010; Geerdink et al, 2012; Fre-
meaux-Bacchi et al, 2013; Lok & Foley, 2013; Campistol
et al, 2015). Among patients enrolled in the Alexion-spon-
sored global aHUS Registry who had no history of treatment
with eculizumab, streptococcal pneumonia and influenza
were observed in 4% of paediatric and 1% of adult patients
(annual interim aHUS Registry analysis – submitted to health
authorities along with Periodic Benefit Risk Evaluation
Report; unpublished observations). Deaths due to sepsis and
Staphylococcus aureus septicaemia have been reported in rare
instances in untreated patients with aHUS (Sellier-Leclerc
et al, 2007; Ardissino et al, 2016). The reporting rate for
Aspergillus infections was 10-fold higher in patients with
aHUS compared with patients with PNH, as expected in
immunosuppressed populations and the comorbidities asso-
ciated with each disease. All patients with an Aspergillus
Table V. Type of meningococcal disease by MedDRA preferred term and event outcomes.
PNH (n = 61), n (%) aHUS (n = 24), n (%) Total* (n = 85), n (%)
MedDRA preferred terms
Meningococcal sepsis 30 (492) 7 (292) 37 (435)
Meningococcal infection 13 (213) 8 (334) 21 (247)
Meningitis meningococcal 13 (213) 5 (208) 18 (212)
Meningococcal bacteraemia 4 (66) 4 (167) 8 (94)
Encephalitis meningococcal 1 (16) 0 1 (12)
Outcomes
Recovered 19 (365) 10 (417) 29 (382)
Fatal† 8 (154) 0 8 (105)
Improved‡ 5 (96) 1 (42) 6 (79)
Recovered with sequelae§ 3 (58) 1 (42) 4 (47)
Ongoing 2 (38) 1 (42) 3 (39)
Unknown 15 (288) 11 (458) 26 (342)
Data expressed as percentage for each reported MedDRA term and corresponding outcomes.
Meningococcal infection: generic term, with no location specified.
aHUS, atypical haemolytic uraemic syndrome; MedDRA, Medical Dictionary for Regulatory Activities; PNH, paroxysmal nocturnal haemoglobin-
uria.
*There may be multiple preferred terms per case.
†Fatal outcomes occurred with equal distribution worldwide. Main cause of death due to delayed diagnosis.
‡Not fully recovered.
§Sequelae: 1 patient experienced amputation of 7 of 10 distal fingers, 1 patient experienced bilateral forefoot amputation, 1 patient experienced
thrombosis of retinal vein and blindness, and 1 patient experienced weakness (which was a pre-existing condition).
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infection had multiple confounding factors, such as solid
organ (renal) transplant or bone marrow transplant, and
were receiving immunosuppressive treatment (e.g., high-dose
steroids, mycophenolate mofetil, ciclosporin, tacrolimus).
Graft-versus-host disease, aplastic anaemia, myelodysplastic
syndrome (MDS) and diabetes were also reported in some
patients. Together, these reports suggest that the above asso-
ciated diseases and concomitant treatments that lead to an
immunosuppressed state may contribute to the occurrence of
serious nonmeningococcal infections in the current analysis,
and do not represent a new safety signal for eculizumab
(Rother et al, 2007).
Exposure to eculizumab during pregnancy was associated
with a comparable rate of live births and a low rate of
maternal complications in contrast to reports of elevated
maternal mortality rates observed among patients with
PNH not receiving eculizumab (Kelly et al, 2015). In aHUS,
use of eculizumab in pregnancy and post-partum is associ-
ated with good maternal and fetal outcomes, including nor-
malization of haematological outcomes and renal function
(Ardissino et al, 2013; Delmas et al, 2013; Zschiedrich et al,
2013; Canigral et al, 2014; Mussoni et al, 2014; De Sousa
Amorim et al, 2015; Demir et al, 2016; Saad et al, 2016;
Servais et al, 2016; Tsai & Kuo, 2016; Andries et al, 2017;
Bruel et al, 2017; Chua et al, 2017; Gately et al, 2017). The
rate of congenital malformation reported in neonates born
to mothers treated with eculizumab lies within the range of
that reported in the general population (UK Teratology
Information Service, 2017). In addition, the overall rate of
miscarriage in this study (158%) was similar to the rate of
pregnancy loss observed in a population of more than
20 000 women in the United States from 1990 to 2011
(197%) (Rossen et al, 2018). Thus, the use of eculizumab
in pregnancy in patients with PNH or aHUS may be
Table VI. Overall serious infections in patients treated with eculizumab.
Infections PNH aHUS Total
Rate, per 100 PY 58 139 79
Age, mean (range), years 515 (7–94) 342 (004–87) 445 (004-94)
<18 years, % 18 189 97
≥18 years, % 861 512 700
Unknown, % 121 299 203
Sex, %
Female 517 588 550
Male 469 359 418
Unknown 14 54 32
As reported percentage of serious infections by causal organism types
Causal organism NOS, % 628 614 622
All bacterial infections among infections (%) 228 192 211
Neisseria* % bacterial infections 133 72 108
Enterococcus or E. coli % bacterial infections 76 151 108
Streptococcus % bacterial infections 67 48 59
Pseudomonas % bacterial infections 65 69 67
Klebsiella % bacterial infections 25 45 33
Tuberculosis % bacterial infections 22 19 22
Haemophilus % bacterial infections 04 05 03
Other (%) bacterial infections 608 591 600
All viral infections among infections (%) 112 138 124
Influenza % viral infections 217 269 243
Herpes zoster % viral infections 112 125 119
Cytomegalovirus % viral infections 27 169 100
BK or JC virus % viral infections 0 69 13
Other % 644 368 525
All fungal infections among infections (%) 24 47 35
Aspergillus % fungal infections 143 321 248
Candida % fungal infections 89 118 107
Other % fungal infections 768 570 645
All sepsis among infections (%) 117 119 118
Total incidence rates are expressed as per 100 PY. Breakdown of incidence rates within subgroups are expressed as a percentage of the total inci-
dence rate by age group, sex, or for each type of serious infections.
aHUS, atypical haemolytic uraemic syndrome; NOS, not otherwise specified (causative infective agent was not reported); PNH, paroxysmal noc-
turnal haemoglobinuria; PY, patient-years.
*Including 17% of disseminated gonococcal infections.
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appropriate and safer than discontinuing or not initiating
eculizumab treatment.
No teratogenic effects in fetuses have been observed thus
far (UK Teratology Information Service, 2017). Teratogeni-
city is unlikely because eculizumab does not bind Fc recep-
tors (Rother et al, 2007) and has low binding affinity for the
neonatal Fc receptor (FcRn), which is a prerequisite for
transport of immunoglobulin G antibodies across the mater-
nofetal barrier (Hallstensen et al, 2015). Eculizumab does not
accumulate in fetal blood and does not influence fetal/neona-
tal complement activity (Hallstensen et al, 2015; Servais et al,
2016). Trans-mammary transportation of antibodies is also
Table VII. Pregnancy outcomes in women treated with eculizumab.
Reported outcomes PNH (n = 206), n (%) aHUS (n = 54), n (%) Total (n = 260), n (%)
Live birth* 150 (728) 32 (593) 182 (700)
Miscarriage or spontaneous abortion 33 (160) 8 (148) 41 (158)
Induced abortion† 16 (78) 11 (204) 27(104)
Stillbirth or fetal death‡ 6 (29) 3 (56) 9 (35)
Maternal death§ 1 (05) 0 1 (04)
Unreported outcomes PNH (n = 129), n (%) aHUS (n = 45), n (%) Total (n = 174), n (%)
Pregnant at time of reporting¶ 98 (760) 38 (844) 136 (782)
Lost to follow-up‡ 31 (240) 7 (156) 38 (218)
Table summarises percentage of reported and unreported pregnancy outcomes for each indication and in total.
aHUS, atypical haemolytic uraemic syndrome; PNH, paroxysmal nocturnal haemoglobinuria.
*Sixty-five live births by C-section.
†Abortion was induced for medical reasons (including 1 ectopic pregnancy) or was the patient’s decision.
‡Including 1 ectopic pregnancy.
§Patient died of enterococcal infection.
¶Includes 4 cases where the pregnancy was not confirmed.
Table VIII. Solid tumours and haematological malignancies in patients treated with eculizumab.
PNH aHUS Total
Rate, per 100 PY 26 31 27
Age, mean (range), years 606 (9–93) 516 (3–84) 519 (3–93)
<18 years, % 09 74 28
≥18 years, % 847 591 771
Unknown, % 144 335 201
Sex, %
Female 461 530 481
Male 521 422 492
Unknown 18 48 27
As reported percentage of malignancies by tumour types
Haematological tumours, % of total malignancies 530* 227 438
Leukaemia, % of haematological tumours 900 403 822
Lymphomas, % of haematological tumours 62 355 107
Other NOS, % of haematological tumours 38 242 71
Solid tumours, % of total malignancies 470 773 728
Gastrointestinal, % of solid tumours 170 180 155
Skin, % of solid tumours 152† 52† 104
Reproductive, % of solid tumours 122 99 101
Breast, % of solid tumours 92 85 79
Other, % of solid tumours (e.g., respiratory, hepatobiliary, CNS, renal; all <5% each) 464 584 561
Total incidence rates are expressed as per 100 PY. Breakdown of incidence rates within subgroups are expressed as a percentage of the total inci-
dence rate by age group, sex, or for each tumour type.
aHUS, atypical haemolytic uraemic syndrome; CNS, central nervous system; NOS, not otherwise specified; PNH, paroxysmal nocturnal
haemoglobinuria; PY, patient-years.
*Of all reported haematological tumours occurring in patients with PNH, 645% were myelodysplastic syndromes.
†Among skin tumours, 25% were melanomas.
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an active mechanism requiring binding to FcRn and, there-
fore, eculizumab is not expected to be found in breast milk
(Cui et al, 2014; Kelly et al, 2015). Based on the current lim-
ited data and literature, continued treatment appears unlikely
to cause adverse effects in infants (Kelly et al, 2015).
The reporting rate for solid and haematological tumours
remained stable over the 10-year assessment period. Impor-
tantly, patients with PNH and aHUS may be predisposed to
developing malignancies. For example, patients with PNH
may also have concurrent bone marrow dysfunction, placing
them at increased risk of developing acute leukaemia (Socie
et al, 1993; Scheinberg et al, 2014). Thus, haematological
malignancy in the setting of PNH is more likely to be a man-
ifestation of underlying abnormalities of haematopoietic
function than an effect of eculizumab. Consistent with a
potential association between malignancy and disease factors,
the current analysis showed diversity in tumour types and
age at onset of malignancies for PNH and aHUS, respec-
tively. Particularly low rates of malignancy were reported in
paediatric patients with PNH and aHUS, consistent with the
rarity of cancer in this age group. Published information on
background incidences of malignancies in patients with PNH
or aHUS, regardless of treatment, is limited. However, some
analyses comparing cohorts of treated and untreated patients
showed no difference in cumulative incidence of clonal evo-
lution to MDS or acute myeloid leukaemia (AML) (Loschi
et al, 2016). In addition, in a systematic review of published
studies in patients with PNH (N = 1665), 51% progressed
to MDS or AML, and malignancy was the cause of death in
119% (Yu et al, 2016). Similar to patients with PNH,
patients with aHUS who undergo transplantation or who
otherwise receive long-term immunosuppressive treatment
are at increased risk of malignancy, which is unlikely to be
related to eculizumab (Villeneuve et al, 2007).
Only 251% of AE reports in the current analysis were
spontaneous, which implies a higher likelihood of perceived
causality by the reporters than in solicited reports. Therefore,
due to the solicited nature of most reporting sources, it is
likely that many, if not the majority, of the most frequently
reported AEs are signs and symptoms of the underlying dis-
ease or are confounded by the patients’ other conditions. For
example, haemolysis, low haemoglobin and fatigue were
among the most frequently reported AEs in patients with
PNH and aHUS, and these AEs are similar to common
symptoms of PNH and aHUS (Sellier-Leclerc et al, 2007;
Peffault de Latour et al, 2008; Noris & Remuzzi, 2009; Brod-
sky, 2014). There were no observed meaningful differences in
the frequency or type of AEs associated with eculizumab
treatment in patients with or without a history of liver dys-
function or history of renal impairment.
There are several limitations of this analysis. First, the AE
data were analysed by the frequency of each reported event
regardless of causality, and not by patient. Patient identifiers,
comparators and denominators were not available for the
calculation of AE rates, and it was not possible to perform
between-group statistical comparisons. Second, data in the
Alexion pharmacovigilance database are structured by ICSRs,
some of which may have contained incomplete information.
Third, despite careful checks for duplication of AE informa-
tion, different sources may have reported some of the same
events, and this analysis probably overestimates AE rates.
Fourth, although AEs may be underreported in post-market-
ing surveillance (Alatawi & Hansen, 2017), this attribute may
be mitigated by the effectiveness of patient support pro-
grammes and close interactions between physicians and
patients. Finally, it was not possible to compare reports by
age, sex, concomitant medications or treatment with eculizu-
mab or to perform longitudinal follow-up of individual
patients. Accordingly, pharmacovigilance data are useful for
the acquisition of trends or safety signals in treated patients
but do not allow for meaningful comparison of incidence
rates for malignancies over time.
Conclusions
This analysis is the largest safety data set to date, represent-
ing more than 10 years of post-marketing pharmacovigilance
surveillance of eculizumab for the treatment of PNH and
aHUS. The overall safety profile of eculizumab is consistent
with that reported from clinical trials. No new safety signals
affecting the benefit-risk profile of eculizumab were detected.
The use of eculizumab in pregnancy appears to have a
favourable benefit-risk profile. The major risk of eculizumab
treatment remains the susceptibility to neisserial infections,
most importantly meningococcal infections. Clinicians
should rely on careful assessment of the potential benefit and
risk of eculizumab for each patient and the implementation
of appropriate monitoring to effectively mitigate the risk of
meningococcal infection.
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